The FDA has proposed policies in the Trump administration's budget to encourage domestic pharmaceutical manufacturing and clinical trials, with Commissioner Marty Makary citing the need to counter China's dominance in early-stage drug development. Key proposals include making U.S. clinical trials easier to run and giving domestic generics manufacturers a one-month advantage over foreign companies in challenging brand drug patents. Separately, the TrumpRx website, which launched in February 2026 with 40 drugs and now offers over 61 medications, will add AbbVie and Genentech products, including Humira at an 86% discount for uninsured patients. The initiatives represent multiple policy levers the administration is deploying to reshore drug manufacturing to the United States.
Aug 10, 2026 · 2 sources
Aug 9, 2026 · 9 sources
Aug 9, 2026 · 6 sources
Aug 7, 2026 · 4 sources
Story comments
Loading comments…